Publications: Adams, Abbie

2022

Huang, D., Thompson, J.A., Chen, S-C, Adams, A., Pitout, I., Lima, A., Zhang, D., Jeffery, R.C.H., Attia, M.S., McLaren, T.L., Lamey, T.M., De Roach, J.N., McLenachan, S., Aung-Htut, M.T., Fletcher, S., Wilton, S.D. and Chen, F.K. (2022) Characterising splicing defects of ABCA4 variants within exons 13–50 in patient-derived fibroblasts. Experimental Eye Research, 225 . Art. 109276.

2021

Flynn, L.L., Mitrpant, C., Adams, A., Pitout, I.L., Stirnweiss, A., Fletcher, S. and Wilton, S.D. (2021) Targeted SMN exon skipping: A useful control to assess in vitro and in vivo splice-switching studies. Biomedicines, 9 (5). Article 552.

Huang, D., Thompson, J.A., McLenachan, S., Chen, S-C, Zhang, D., Heath Jeffery, R.C., Attia, M., McLaren, T.L., Lamey, T.M., De Roach, J.N., Aung-Htut, M.T., Adams, A., Fletcher, S., Wilton, S. and Chen, F.K. (2021) Using induced pluripotent stem cell-derived retinal pigment epithelial cells to model splicing defects of ABCA4 c.5461-10T > C detected in an Australian Stargardt disease cohort. Investigative Ophthalmology and Visual Science, 62 (8). Art. 3294.

2020

Li, D., Adams, A.M., Johnsen, R.D., Fletcher, S. and Wilton, S.D. (2020) Morpholino oligomer-induced dystrophin isoforms to map the functional domains in the dystrophin protein. Molecular Therapy - Nucleic Acids, 22 . pp. 263-272.

Huang, D., Thompson, J.A., Charng, J., Chelva, E., McLenachan, S., Chen, S‐C, Zhang, D., McLaren, T.L., Lamey, T.M., Constable, I.J., De Roach, J.N., Aung‐Htut, M.T., Adams, A.M., Fletcher, S., Wilton, S.D. and Chen, F.K. (2020) Phenotype–genotype correlations in a pseudodominant Stargardt disease pedigree due to a novel ABCA4 deletion–insertion variant causing a splicing defect. Molecular Genetics & Genomic Medicine . Art. e1259.

2019

Servián-Morilla, E., Cabrera-Serrano, M., Rivas-Infante, E., Carvajal, A., Lamont, P.J., Pelayo-Negro, A.L., Ravenscroft, G., Junckerstorff, R., Dyke, J.M., Fletcher, S., Adams, A.M., Mavillard, F., Fernández-García, M.A., Nieto-González, J.L., Laing, N.G. and Paradas, C. (2019) Altered myogenesis and premature senescence underlie human TRIM32-related myopathy. Acta Neuropathologica Communications, 7 (1).

2018

Viola, H.M., Johnstone, V.P.A., Adams, A.M., Fletcher, S. and Hool, L.C. (2018) A morpholino oligomer therapy regime that restores mitochondrial function and prevents mdx cardiomyopathy. JACC: Basic to Translational Science, 3 (3). pp. 391-402.

Hoffmann, K., Milech, N., Juraja, S.M., Cunningham, P.T., Stone, S.R., Francis, R.W., Anastasas, M., Hall, C.M., Heinrich, T., Bogdawa, H.M., Winslow, S., Scobie, M.N., Dewhurst, R.E., Florez, L., Ong, F., Kerfoot, M., Champain, D., Adams, A.M., Fletcher, S., Viola, H.M., Hool, L.C., Connor, T., Longville, B.A.C., Tan, Y-F, Kroeger, K., Morath, V., Weiss, GA., Skerra, A., Hopkins, R.M. and Watt, P.M. (2018) A platform for discovery of functional cell-penetrating peptides for efficient multi-cargo intracellular delivery. Scientific Reports, 8 (1).

2017

Le, B.T., Adams, A.M., Fletcher, S., Wilton, S.D. and Veedu, R.N. (2017) Rational design of short locked Nucleic Acid-Modified 2′- O -Methyl antisense oligonucleotides for efficient exon-skipping in vitro. Molecular Therapy - Nucleic Acids, 9 . pp. 155-161.

Viola, H.M., Johnstone, V.P.A., Adams, A.M., Fletcher, S. and Hool, L.C. (2017) Treatment of Adult mdx Mice with Phosphorodiamidate Morpholino Oligomer Restores Cardiac Mitochondrial Energetics and Prevents the Dystrophic Cardiomyopathy. Biophysical Journal, 112 (3). 245a.

2016

Fraidenraich, D., Toh, Z.Y.C., Aung-Htut, M.T., Pinniger, G., Adams, A.M., Krishnaswarmy, S., Wong, B.L., Fletcher, S. and Wilton, S.D. (2016) Deletion of dystrophin In-Frame Exon 5 leads to a severe phenotype: Guidance for Exon skipping strategies. PloS one, 11 (1). e0145620.

2015

Veedu, R.N., Adams, A., Fletcher, S., Shastri, A., Wengel, J. and Wilton, S. (2015) Locked nucleic acid-modified antisense oligonucleotides for enhanced exon skipping in Duchenne muscular dystrophy. The Journal of Gene Medicine, 17 (8 - 9). O17.

Wilton, S., Adams, A., Greer, K., West, K.A.ORCID: 0000-0002-7036-5334 and Fletcher, S. (2015) Therapeutic alternative splicing: an update on Duchenne muscular dystrophy clinical trials and other applications. The Journal of Gene Medicine, 17 (8 - 9). O19.

2014

Fletcher, S., Adams, A.M., Greer, K., Johnsen, R. and Wilton, S.D. (2014) Antisense mediated exon selection to alter gene expression. In: PAG Asia 2014, 19 - 21 May 2014, Singapore.

2013

Fletcher, S., Viola, H.M., Adams, A.M., Wilton, S.D. and Hool, L.C. (2013) PMO-mediated dystrophin exon 23 skipping restores nitochondrial function in the MDX heart. In: 8th Australasian Gene Therapy Society Meeting, 8 - 10 May 2013, Sydney, Australia.

2012

Fletcher, S., Adams, A.M., Greer, K., Johnsen, R.D., Adkin, C. and Wilton, S.D. (2012) G.P.78 Dystrophin isoforms with incomplete β dystroglycan and syntrophin binding domains retain partial function. In: 17th International Congress of The World Muscle Society, 9 - 13 October 2012, Perth, Western Australia.

2011

Wilton, S.D., Adams, A.M., Adkin, C., Greer, K., Johnsen, R. and Fletcher, S. (2011) Transient mouse models for the preclinical evaluation of therapeutic dystrophin exon skipping strategies. In: UK Neuromuscular Translational Research Conference, 29 - 30 March 2011, London, England.

Fletcher, S., Adams, A.M., Adkin, C., Greer, K., Johnsen, R. and Wilton, S. (2011) Transient mouse models for the preclinical evaluation of therapeutic dystrophin exon skipping strategies. In: 7th Australasian Gene Therapy Society Meeting, 4 - 6 May 2011, University of Melbourne, Melbourne.

2010

Fletcher, S., Adams, A.M., Johnsen, R.D., Greer, K., Mitrpant, C., Moulton, H.M., Kole, R. and Wilton, S.D. (2010) Concurrent administration of prednisolone and peptide conjugated PMOs is not contra-indicated in the MDX mouse. In: 15th International Congress of The World Muscle Society, 12 - 16 October 2010, Kumamoto, Japan.

Fletcher, S., Adams, A.M., Greer, K., Johnsen, R. and Wilton, S.D. (2010) Induced splice-switching to study dystrophin isoform function and expression. In: OzBio, 26 September - 1 October, Melbourne, Australia.

2009

Fletcher, S., Adams, A.M., Johnsen, R., Greer, K. and Wilton, S. (2009) Induced non-productive splicing to study muscle gene expression. In: 6th Australasian Gene Therapy Society Meeting, 29 April - 1 May 2009, Kerry Packer Education Centre. Royal Prince Alfred Hospital, Sydney, NSW.

Fletcher, S., Adams, A.M., Johnsen, R., Greer, K. and Wilton, S. (2009) Induced non-productive splicing to study muscle gene expression. In: 33rd HGSA Annual Scientific Meeting, 3 - 6 May 2009, Fremantle, Western Australia.

Adams, A.M., Fletcher, S., Ly, T., Johnsen, R. and Wilton, S. (2009) Normalisation of gene expression in MDX mice muscle. In: 6th Australasian Gene Therapy Society Meeting, 29 April - 1 May 2009, Kerry Packer Education Centre. Royal Prince Alfred Hospital, Sydney, NSW.

Wilton, S., Adams, A.M., Meloni, P., Johnsen, R., Forrest, S., Greer, K., Stone, L., Mitrpant, C. and Fletcher, S. (2009) Splice intervention to treat duchenne muscular dystrophy and beyond. In: 33rd HGSA Annual Scientific Meeting, 3 - 6 May 2009, Fremantle, Western Australia.

Adams, A.M., Fletcher, S., Ly, T., Johnsen, R. and Wilton, S. (2009) Transcriptome patterns show normalization of muscle gene expression after restoration of dystrophin in MDX mice by exon skipping. In: 33rd HGSA Annual Scientific Meeting, 3 - 6 May 2009, Fremantle, Western Australia.

2007

Adams, A.M., Harding, P.L., Iversen, P.L., Coleman, C., Fletcher, S. and Wilton, S.D. (2007) Antisense oligonucleotide induced exon skipping and the dystrophin gene transcript: Cocktails and chemistries. In: 5th Australasian Gene Therapy Society Meeting, 18 - 20 April 2007, Shine Dome Academy of Science, Canberra.

Wilton, S.D., Adams, A.M., Harding, P.L., McClorey, G., Coleman, C. and Fletcher, S. (2007) Antisense oligonucleotide-induced exon skipping across the human dystrophin gene transcript. In: 5th Australasian Gene Therapy Society Meeting, 18 - 20 April 2007, Shine Dome Academy of Science, Canberra.

Adams, A.M., McClorey, G., Moulton, H.M., Inversen, P.L., Rasko, J.E., Ryan, M., Fletcher, S. and Wilton, S.D. (2007) Induced dystrophin exon skipping in human muscle explants. In: 5th Australasian Gene Therapy Society Meeting, 18 - 20 April 2007, Shine Dome Academy of Science, Canberra.

Harding, P.L., Adams, A.M., Iversen, P., Fletcher, S. and Wilton, S.D. (2007) Induced exon skipping: AO design is more important than chemistry. In: 5th Australasian Gene Therapy Society Meeting, 18 - 20 April 2007, Shine Dome Academy of Science, Canberra.

Fletcher, S., Adams, A.M., Harding, P.L., McClorey, G., Muntoni, F., Iversen, P.L. and Wilton, S.D. (2007) A personalised genetic treatment for DMD. In: 5th Australasian Gene Therapy Society Meeting, 18 - 20 April 2007, Shine Dome Academy of Science, Canberra.